Jyong Biotech Ltd. income statement MENS
It recorded a net loss of $4.7 million. Diluted earnings per share were -$0.06.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
|---|---|
| Research and development |
1
|
| Selling, general and administrative |
2
|
| Operating income |
-3
|
| Other income (expense) |
-2
|
| Pretax income |
-5
|
| Net income |
-5
|
| Basic EPS |
-0.06
|
| Diluted EPS |
-0.06
|
| Weighted average shares, basic |
73
|
| Weighted average shares, diluted |
73
|
| Other measures | |
| Depreciation and amortization |
0
|
| EBITDA |
-3
|
| Interest coverage |
-1.03x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MENS (Nasdaq)
- Incorporated in
- Cayman Islands
- Headquarters
- New Taipei City
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1954488
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.